
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences Inc. is demonstrating a positive outlook with an upward revision of its FY26 EPS estimates, reflecting a decrease in projected losses from $(8.63) to $(4.17), indicating improved financial performance expectations. The anticipated FDA approval of the MyoVista device and the ongoing rollout of the MyoVista Insights cloud platform position the company for significant market expansion in cardiac diagnostics. Moreover, the company's new price target of $9.20, derived from a Net Present Value analysis, suggests considerable upside potential, supported by the increasing recognition of AI technology in transforming ECG diagnostics for improved early heart disease detection.
Bears say
HeartSciences Inc. faces significant challenges that contribute to a negative outlook on its stock, particularly due to a substantial reduction in projected revenues, with FY2026 estimates revised from $1.2 million to $0.1 million primarily due to FDA-related delays. Additionally, the company is exposed to numerous risks including potential liquidity issues, the need for successful clinical trial outcomes, regulatory approval hurdles, and commercialization difficulties, all of which could adversely affect its operations. The overall environment is further complicated by competition and fluctuating investor sentiment towards healthcare stocks, undermining confidence in the company’s ability to achieve its objectives.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares